Subtype
Small Cell Neuroendocrine Carcinoma
CI-CAN-00003964SCNECExplore in graph →
396 active trials6 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003964SCNECExplore in graph →
Clinical trials
1,165 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (168)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00375193 | Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy | completed | Phase 2 | 75 | CelgeneINDUSTRY | 3 | Oct 24, 2019 | clinicaltrials |
| NCT02030184 | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas | withdrawn | Phase 1 / Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT04128800 | Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT00483509 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma(NGR007) | completed | Phase 2 | 28 | AGC Biologics S.p.A.INDUSTRY | 1 | Oct 4, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01025284 | A Study for Participants With Small-Cell Lung Cancer | completed | Phase 2 | 64 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 17, 2019 | clinicaltrials |
| NCT03994744 | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | unknown | Phase 2 | 68 | Hunan Cancer HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT04056949 | Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy | unknown | Phase 2 | 30 | Junling LiOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT01266447 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT02109016 | A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations | terminated | Phase 2 | 18 | Clovis Oncology, Inc.INDUSTRY | 5 | Jul 29, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT01439568 | A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT03059797 | Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) | completed | Phase 2 | 120 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT01253369 | Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01173523 | Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 25 | David M. Jackman, MDOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02605811 | Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer | unknown | Phase 2 | 426 | Guangzhou Medical UniversityOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT03841136 | Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT02542137 | Abscopal Effect for Metastatic Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 0 | Mar 21, 2019 | clinicaltrials |
| NCT03239171 | Bioinformation Therapy for Lung Cancer | completed | Phase 2 / Phase 3 | 120 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03811379 | Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy | unknown | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT00309959 | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01722292 | A Study of LY2940680 in Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 26 | Eli Lilly and CompanyINDUSTRY | 2 | Dec 28, 2018 | clinicaltrials |
| NCT01497873 | A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer | completed | Phase 2 | 164 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Dec 27, 2018 | clinicaltrials |
| NCT02038647 | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 178 | Millennium Pharmaceuticals, Inc.INDUSTRY | 10 | Dec 27, 2018 | clinicaltrials |
| NCT03780283 | Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC | unknown | Phase 2 | 30 | First Hospital of Shijiazhuang CityOTHER | 1 | Dec 21, 2018 | clinicaltrials |
| NCT03781869 | Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer | unknown | Phase 2 | 116 | Third Military Medical UniversityOTHER | 0 | Dec 20, 2018 | clinicaltrials |
| NCT03366675 | AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] | terminated | Phase 2 | 15 | Samsung Medical CenterOTHER | 1 | Nov 27, 2018 | clinicaltrials |
| NCT02200081 | Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC(IMPULSE) | completed | Phase 2 | 103 | Mologen AGINDUSTRY | 4 | Nov 15, 2018 | clinicaltrials |
| NCT03732846 | Anlotinib in Treatment of Recurrent Small Cell Lung Cancer | unknown | Phase 2 | 43 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00702962 | Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 8 | Milton S. Hershey Medical CenterOTHER | 1 | Oct 22, 2018 | clinicaltrials |
| NCT02688907 | Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation | terminated | Phase 2 | 7 | Samsung Medical CenterOTHER | 1 | Sep 20, 2018 | clinicaltrials |
| NCT03106155 | Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification([SUKSES-D]) | terminated | Phase 2 | 4 | Samsung Medical CenterOTHER | 1 | Sep 20, 2018 | clinicaltrials |
| NCT01901653 | Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 82 | StemcentrxINDUSTRY | 1 | Aug 9, 2018 | clinicaltrials |
| NCT00298896 | Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer | completed | Phase 2 | 55 | Sunesis PharmaceuticalsINDUSTRY | 2 | Jul 26, 2018 | clinicaltrials |
| NCT00098956 | 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2018 | clinicaltrials |
| NCT00527735 | Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 334 | Bristol-Myers SquibbINDUSTRY | 8 | Jul 18, 2018 | clinicaltrials |
| NCT03410368 | NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer. | unknown | Phase 2 | 120 | jiuwei cuiOTHER | 1 | Jul 17, 2018 | clinicaltrials |
| NCT01553916 | Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain | completed | Phase 1 / Phase 2 | 19 | Washington University School of MedicineOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02331251 | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | terminated | Phase 1 / Phase 2 | 81 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02748889 | Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Giuseppe GiacconeOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02161419 | RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer(CONCEPT-SCLC) | terminated | Phase 2 | 142 | BayerINDUSTRY | 9 | Jun 25, 2018 | clinicaltrials |
| NCT00445198 | A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies | completed | Phase 1 / Phase 2 | 86 | AbbVie (prior sponsor, Abbott)INDUSTRY | 3 | Jun 6, 2018 | clinicaltrials |
| NCT02261805 | A Phase I/II Study of Ganetespib in Combination With Doxorubicin | terminated | Phase 1 / Phase 2 | 11 | Georgetown UniversityOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT00265200 | Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer | terminated | Phase 2 | 28 | University of LouisvilleOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01237678 | A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 181 | ImmunoGen, Inc.INDUSTRY | 4 | Jan 18, 2018 | clinicaltrials |
| NCT00528645 | AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2017 | clinicaltrials |
| NCT03135977 | Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy | unknown | Phase 2 | 36 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 7, 2017 | clinicaltrials |
| NCT00374140 | Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer | completed | Phase 2 | 40 | Ahmad TarhiniOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT00003496 | Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer | terminated | Phase 2 | 4 | Burzynski Research InstituteOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT02876081 | Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex(THEN) | withdrawn | Phase 2 | 0 | Fondation Hôpital Saint-JosephOTHER | 1 | Sep 11, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Oct 24, 2019source: clinicaltrials